Want to see TSE:CRDL full AI Analyst Report?
CRDL Stock Chart & Stats
C$2.06
-C$0.08(-4.06%)
At close: 4:00 PM EST
C$2.06
-C$0.08(-4.06%)
Day’s Range― - ―
52-Week RangeC$1.23 - C$2.33
Previous CloseN/A
Volume34.34K
Average Volume (3M)136.50K
Market Cap
C$194.81M
Enterprise ValueC$178.43
Total Cash (Recent Filing)C$27.67M
Total Debt (Recent Filing)C$116.41K
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding115,272,240
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.93Price Target Upside479.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal reported debt materially reduces refinancing and solvency risk for a pre-revenue biotech. This durable balance-sheet conservatism gives management optionality to pursue clinical programs and time fundraising strategically without immediate debt-service pressure.
Focused Cardiovascular PipelineCardiol's focused strategy targeting inflammation and fibrosis in heart failure uses differentiated cannabidiol-based formulations. Addressing persistent unmet needs in cardiology provides a durable market opportunity and potential scientific differentiation if clinical efficacy and regulatory paths validate the approach.
Improving Cash OutflowsManagement reports narrowing cash outflows versus prior years, suggesting improved cash discipline or slower burn. If sustained, this extends runway, lowers near-term dilution risk and supports continuity of pivotal studies—an important structural improvement for a development-stage firm.
Bears Say
Pre-revenue StatusThe company remains pre-revenue with a large trailing net loss, meaning no commercial cash flows to fund operations. This structural absence of revenue forces ongoing dependence on external capital, amplifying financing and execution risk over multiple reporting periods.
Sustained Cash BurnPersistent negative operating and free cash flow at material levels implies recurring financing needs. Over the medium term this increases dilution risk, constrains strategic flexibility, and can disrupt long-term R&D planning if capital markets or partner funding become less accessible.
Limited Internal ScaleA small team of 18 limits internal capacity to run multiple complex trials, manage regulatory interactions, and commercialize later-stage programs. This structural resource constraint raises reliance on CROs and partners, increasing execution risk and potential delays in development timelines.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.23 and its highest was C$2.33 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is C$194.81M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 115,272,240 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$11.93 (479.24% Upside)
C$11.93 (479.24% Upside)
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
27.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$11.93
▲(479.24% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―